Yoshidome Katsuhide, Imabun Shigeru, Nakahara Masaaki, Hiraoka Kazuya, Yamagami Yuko, Tsujimoto Masahiko, Nakao Kazuyasu
Dept. of Surgery, Osaka Police Hospital.
Gan To Kagaku Ryoho. 2006 Oct;33(10):1453-6.
We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer. The patient had a complete response (CR) to pulmonary metastases, and carcinoembryonic antigen (CEA) level had normalized from 46.4 ng/ml to 0.6 ng/ml. Left mastectomy was performed in order to control bleeding from tumors. No adverse events attributable to medication were observed. The concomitant administration of capecitabine and trastuzumab is a promising therapy with the potential to greatly improve patient quality of life (QOL).
我们对一名73岁、下肢功能受损且被诊断为双侧乳腺癌的女性患者，同时给予卡培他滨（2400毫克/天，持续21天，随后间隔7天）和曲妥珠单抗（2毫克/千克，每周一次）。该患者肺部转移灶完全缓解（CR），癌胚抗原（CEA）水平从46.4纳克/毫升恢复正常至0.6纳克/毫升。为控制肿瘤出血，实施了左侧乳房切除术。未观察到与药物相关的不良事件。卡培他滨和曲妥珠单抗的联合给药是一种有前景的治疗方法，有可能极大地改善患者生活质量（QOL）。
